#Switzerland #avacopan #CSL Vifor #St. Gallen #TAVNEOS

TAVNEOS® Marketing Authorization Revocation Recommendation

On June 26, 2026, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced significant news regarding TAVNEOS® (avacopan), a treatment for severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended revoking the marketing authorization for TAVNEOS in the European Union (EU), a major development affecting many patients.

Background

TAVNEOS has been a crucial treatment option for patients suffering from ANCA-associated vasculitis, a condition where the immune system mistakenly attacks blood vessels, leading to inflammation and potential damage to vital organs, primarily the kidneys and lungs. These disorders require careful management due to their life-threatening nature. TAVNEOS, developed by ChemoCentryx, is used in conjunction with treatments like rituximab or cyclophosphamide to help mitigate the severity of these conditions.

This recommendation from the CHMP stems from an Article 20 non-pharmacovigilance procedure initiated due to concerns about the data management practices observed in the pivotal Phase 3 ADVOCATE trial. Upon evaluation, the CHMP concluded that the authorization for TAVNEOS should be revoked, and the final decision by the European Commission (EC) is expected soon.

Impact on Patients

The recommendation signifies that no new patients in the EU will be administered TAVNEOS, while those currently undergoing treatment are urged to discuss their options with healthcare providers. This transition phase comes at a challenging time for patients, particularly considering TAVNEOS's significant role in their treatment regimen. Dr. Bill Mezzanotte, from CSL, emphasized the company's commitment to patient care and its dedication to providing innovative therapeutic options for rare diseases.

Patients facing the possibility of transitioning from TAVNEOS to alternative treatments may experience concerns regarding the continuity of their care. Healthcare professionals are advised to closely collaborate with regulatory authorities to facilitate this process and ensure that patient needs are addressed during the transition. VFMCRP and CSL are actively working alongside physicians and patient organizations to provide ongoing support and ensure a smooth changeover.

ANCA-associated Vasculitis: A Quick Overview

ANCA-associated vasculitis comprises diseases where inflammation leads to serious complications. Patients experience a diminished quality of life due to the dual burden of the disease and the treatment itself, which may involve glucocorticoids that have their own adverse effects. The need for effective treatments remains pressing, given the potential for severe complications both from the condition and its management.

About TAVNEOS®

TAVNEOS is an orally administered medication functioning as a selective inhibitor of the complement C5a receptor (C5aR1). By blocking this receptor on inflammatory cells, TAVNEOS mitigates the damaging effects associated with C5a activation without impairing other immune responses. This mode of action has made TAVNEOS an innovative treatment option for those struggling with ANCA-associated vasculitis.

Company Information

CSL Vifor, a global leader in pharmaceuticals concerning iron deficiency and nephrology, has positioned itself as a key player in delivering advanced therapies globally. Headquartered in St. Gallen, Switzerland, it operates in partnership with various pharmaceutical firms to ensure cutting-edge treatments reach patients who need them most.

In light of this recent recommendation, ongoing communications from both CSL and healthcare providers will be critical in navigating the challenges ahead for patients reliant on TAVNEOS. The healthcare community remains dedicated to supporting these individuals through this transition, highlighting the importance of prioritizing patient care and treatment efficacy.